Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 8/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.43 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.43 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.43 |
| ▸ | GCGR | P47871 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 8/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.39 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5500967 | 0.84 | MAPK14 (0.49) | IDO1ALOX5MAPK14MAPK13MAPK12 | |
| SCHEMBL5497054 | 0.84 | MAPK14 (0.49) | IDO1ALOX5MAPK14MAPK13MAPK12 | |
| SCHEMBL5138611 | 0.78 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11TGFBR1 | |
| SCHEMBL6178729 | 0.78 | MEN1 (0.38) | MAPK14TGFBR1FYNTP53 | |
| SCHEMBL5497235 | 0.75 | TGFBR1 (0.70) | ALOX5MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5139077 | 0.72 | TGFBR1 (0.56) | MAPK14MAPK13MAPK12MAPK11TGFBR1 | |
| SCHEMBL5497047 | 0.72 | TGFBR1 (0.54) | IDO1ALOX5MAPK14MAPK13MAPK12 | |
| SCHEMBL5107624 | 0.72 | TGFBR1 (0.55) | MAPK14TGFBR1PRKD1 | |
| SCHEMBL4489424 | 0.71 | TGFBR1 (0.54) | IDO1MAPK14MAPK13MAPK12MAPK11 | |
| SCHEMBL5503286 | 0.71 | TGFBR1 (0.74) | MAPK14MAPK13MAPK12MAPK11TGFBR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906089-B2 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1268465-B1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2005-06-01 | — | — | EP | disclosed |
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-08-07 | — | — | US | disclosed |
| EP-1268465-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001072737-A1 | TRIARYLIMIDAZOLE DERIVATIVES AS CYTOKINE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149277-A1 | Triarylimidazole derivatives as cytokine inhibitors | IL2, IL2RA, IL6ST | IDO1 175/4885ALOX5 2738/4885MAPK14 306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.